Does deuterated colexitinib require patients to take it for a long time?

Deucravacitinib is a drug targeting the immune system and is mainly used to treat immune-mediated diseases such as moderate to severe plaque psoriasis. Since its mechanism of action is to regulate the immune response by inhibiting tyrosine kinase 2 (TYK2), its use often requires long-term maintenance to ensure that the disease is effectively controlled.

For chronic immune diseases such as psoriasis, patients usually need to take deuterated coxitinib for a long time to maintain the stability of the disease. Psoriasis is a chronic, relapsing disease, and although medications can relieve symptoms in the short term, symptoms often return quickly once treatment is stopped. Therefore, as an immunomodulatory drug, deuterated colexitinib usually requires long-term use to ensure that the drug continues to suppress the immune response and prevent recurrence of the disease.

Long-term use of deuterated colexitinib is not suitable for all patients, but for most patients with psoriasis, especially those whose disease is more severe or difficult to control, long-term use of this drug is a routine treatment option. The efficacy of deuterated colexitinib gradually appears, and it usually takes weeks to months to observe significant clinical improvement. Therefore, in the early stages of treatment, patients need to be patient enough, strictly abide by the doctor's recommendations, and continue to take the drug.

During the treatment process, doctors usually regularly evaluate the effects and side effects of the drug based on the patient's specific situation. If the drug works well and the side effects are manageable, the patient is usually advised to continue taking it long-term to maintain the stability of the condition. However, once the condition is significantly improved and assessed by a doctor, some patients may gradually reduce the use of the drug or even discontinue the drug under the guidance of the doctor, but this needs to be done under the supervision of a medical professional to avoid sudden discontinuation of the drug, which may lead to a recurrence of the condition.

Reference materials:https://go.drugbank.com/drugs/DB16650